AbbVie stock target cut, keeps Buy rating on growth outlook
Guggenheim Securities adjusted its financial outlook for shares of AbbVie Inc . (NYSE:ABBV), reducing the price target to $212 from the previous $221, while still recommending a Buy rating for the ...
AbbVie price target lowered to $212 from $221 at Guggenheim
Guggenheim analyst Vamil Divan lowered the firm’s price target on AbbVie (ABBV) to $212 from $221 and keeps a Buy rating on the shares. The ...
clinicaltrialsarena13h
Boehringer Ingelheim announces Phase III schizophrenia failures
The company said that all of its CONNEX trials failed to meet expectations showing no impact on patients living with ...
pharmaphorum13h
Boehringer drug for brain fog in schizophrenia fails trial
As a result of the disappointing results, Boehringer said that it was abandoning a long-term extension trial called CONNEX-X, ...
Optimistic Outlook on AbbVie’s Emraclidine Strategy: A High-Reward Investment Opportunity
Leerink Partners analyst David Risinger has reiterated their bullish stance on ABBV stock, giving a Buy rating yesterday.Stay Ahead of the ...